<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/227602-a-process-for-the-preparation-of-n-arylmorpholine-compound by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 07:35:51 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 227602:A PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINE COMPOUND</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">A PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINE COMPOUND</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Process for the preparation of compounds of the formula I R1 denotes NO2, CN, COOR3, CONCR3)2, COR3, SO2R4, SO2N(R3)2, CF3, F or Cl, R2 denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3COOR3, NR3SO2A, -[C(R5)2]n-Ar, -[C(R5)2]n-Het, -[C(R5)2]n- cycloalkyl, COR3, SO2N(R3)2 or SO2R4, R3 denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het, R4 denotes A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het, R5 denotes H or A&#x27;, Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2 or S(O)nA, Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2, S(O)nA and/or carbonyl oxygen (=O), A&#x27; denotes unbranched or branched alkyl having 1-6 C atoms, A denotes unbranched, branched or cylic alkyl having 1-12 C atoms, in which one or two CH2 groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or in addition 1-7 H atoms may be replaced by F, Hal denotes F, CI, Br or I, n denotes 0, 1 or 2, m denotes 0, 1, 2, 3 or 4, and salts thereof, characterised in that a) a compound of the formula II X-NH2 II in which X has the meaning indicated above, to give a compound of the formula III is reacted with 5-chloro-2,3-dihydro-1,4-dioxin in which X has the meaning indicated above, b) then a compound of the formula III is cyclised to give a compound of the formula I, c) the latter is optionally converted into its salt by converting a base or acid of the formula I into one of its salts.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td> <br><br>
Process for the preparation of N-arylmorpholinones<br>
The invention relates to a process for the preparation of compounds of the<br>
formula I<br><br>
R1 denotes NO2, CN, COOR3, CON(R3)2, COR3, SO2R4, SO2N(R3)2,<br>
CF3, F or CI,<br>
R2 denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2,<br>
NR3COA, NR3CON(R3)2, NR3COOR3, NR3SO2A, -[C(R5)2]n-Ar,<br>
-[C(R5)2]n-Het, -[C(R5)2]n-cycloalkyl, COR3, SO2N(R3)2 or SO2R4,<br>
R3 denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R4 denotes A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R5 denotes H or A',<br>
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted<br>
by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA,<br>
NR5SO2A, COR5, SO2N(R5)2 or S(O)nA,<br>
Het denotes a mono- or bicyclic saturated, unsaturated or aromatic<br>
heterocycle having 1 to 4 N, O and/or S atoms which is unsubstituted<br>
or mono- or disubstituted by Hal, A, OR5, N(R5)2, NO2, CN,<br>
COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2, S(O)nA<br>
and/or carbonyl oxygen (=0),<br>
A' denotes unbranched or branched alkyl having 1-6 C atoms,<br><br>
A	denotes unbranched, branched or cylic alkyl having 1-12 C atoms,<br>
in which one or two CH2 groups may be replaced by O or S atoms<br>
and/or by -CH=CH- groups and/or in addition 1-7 H atoms may be<br>
replaced by F,<br>
Hal denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
m	denotes 0, 1, 2, 3 or 4,<br>
and salts thereof, characterised in that<br>
a)	a compound of the formula II<br>
X-NH2	II<br>
in which<br>
X has the meaning indicated above,<br>
is reacted with 5-chloro-2,3-dihydro-1,4-dioxin<br><br>
to give a compound of the formula III<br><br>
in which<br>
X has the meaning indicated above,<br>
b)	then a compound of the formula III is cyclised to give a compound of<br>
the formula I,<br>
and<br>
c)	the latter is optionally converted into its salt<br><br>
by converting a base or acid of the formula I into one of its salts.<br>
The invention had the object of finding novel improved processes for the<br>
preparation of precursors of factor Xa inhibitors.<br>
Compared with known processes from the prior art, the process according<br>
to the invention is shorter and more efficient.<br>
Factor Xa inhibitors can be employed for combating and preventing<br>
thromboembolic diseases, such as thrombosis, myocardial infarction, arteriosclerosis,<br>
inflammation, apoplexy, angina pectoris, restenosis after<br>
angioplasty and claudicatio intermittens.<br>
Factor Xa is one of the proteases involved in the complex process of blood<br>
coagulation. Factor Xa catalyses the conversion of prothrombin into thrombin.<br>
Thrombin cleaves fibrinogen into fibrin monomers, which, after cross-<br>
linking, make an elementary contribution to thrombus formation. Activation<br>
of thrombin may result in the occurrence of thromboembolic diseases.<br>
However, inhibition of thrombin may inhibit the fibrin formation involved in<br>
thrombus formation.<br>
The inhibition of thrombin can be measured, for example by the method of<br>
G. F. Cousins et al. in Circulation 1996, 94, 1705-1712.<br>
Inhibition of factor Xa can thus prevent the formation of thrombin.<br>
The inhibition of factor Xa and the measurement of the anticoagulant and<br>
antithrombotic activity can be determined by conventional in-vitro or in-vivo<br>
methods. A suitable method is described, for example, by J. Hauptmann et<br>
al. in Thrombosis and Haemostasis 1990, 63, 220-223.<br>
The inhibition of factor Xa can be measured, for example by the method of<br>
T. Hara etal. in Thromb. Haemostas. 1994, 71, 314-319.<br><br>
Coagulation factor VIIa initiates the extrinsic part of the coagulation cas-<br>
cade after binding to tissue factor and contributes to the activation of factor<br>
X to give factor Xa. Inhibition of factor VIIa thus prevents the formation of<br>
factor Xa and thus subsequent thrombin formation.<br>
The inhibition of factor VIIa and the measurement of the anticoagulant and<br>
antithrombotic activity can be determined by conventional in-vitro or in-vivo<br>
methods. A conventional method for the measurement of the inhibition of<br>
factor VIIa is described, for example, by H. F. Ronning et al. in Thrombosis<br>
Research 1996, 84, 73-81.<br>
Coagulation factor IXa is generated in the intrinsic coagulation cascade<br>
and is likewise involved in the activation of factor X to give factor Xa. Inhibition<br>
of factor IXa can therefore prevent the formation of factor Xa in a<br>
different way.<br>
The inhibition of factor IXa and the measurement of the anticoagulant and<br>
antithrombotic activity can be determined by conventional in-vitro or in-vivo<br>
methods. A suitable method is described, for example, by J. Chang et al.<br>
in Journal of Biological Chemistry 1998, 273, 12089-12094.<br>
A correlation between tissue factor TF / factor VIIa and the development of<br>
various types of cancer has been indicated by T.Taniguchi and<br>
N.R.Lemoine in Biomed. Health Res. (2000), 41 (Molecular Pathogenesis<br>
of Pancreatic Cancer), 57-59. The publications listed below describe an<br>
antitumoural action of TF-VII and factor Xa inhibitors for various types of<br>
tumour:<br>
K.M. Donnelly et al. in Thromb. Haemost. 1998; 79: 1041-1047;<br>
E.G. Fischer et al. in J. Clin. Invest. 104: 1213-1221 (1999);<br>
B.M. Mueller et al. in J. Clin. Invest. 101: 1372-1378 (1998);<br>
M.E. Bromberg et al. in Thromb. Haemost. 1999; 82: 88-92.<br>
WO 02/057236 describes other processes and morpholinone precursors.<br><br>
The following methods for the preparation of 2-(2-chloroethoxy)acet-<br>
amides are known in the literature:<br><br>
This method is described, for example, in US 3 074 939, BE 776767<br>
and DE 1922613.<br><br>
This method is described, for example, in G. May, D. Peteri, Arzneim.-<br>
Forsch. (Drug Res.) 23, 718 (1973).<br><br>
This method is described, for example, in DE 2150075.<br>
However, these methods have disadvantages. Thus, many reaction<br>
steps are necessary or the starting materials are expensive.<br><br>
M. J. Astle, J. D. Welks, J. Org. Chem. 26, 4325 (1961) disclose the<br>
following reaction:<br><br>
We have found, surprisingly, that arylamines, so long as they have a<br>
pKa of less than or equal to 3, also react with 2-chlorodioxene to give<br>
2-(2-chloroethoxy)acetamides.<br><br>
In view of M. J. Astle, J. D. Welks, J. Org. Chem. 26, 4325 (1961), this<br>
is unexpected since amines, such as ammonia, benzylamine, 8-amino-<br>
quinoline or 4-methoxyaniline, do not react or react very poorly.<br>
Comparison of pKa values:<br>
Benzylamine	9.5<br>
Ammonia	9.24<br>
8-Aminoquinoline	0.7 (NH2 group) and 4.0 (quinoline nitrogen). The<br>
basic quinoline nitrogen prevents the reaction.<br>
4-Methoxyaniline	5.4<br>
4-Nitroaniline	1.0<br>
4-Cyanoaniline	1.7<br>
3-Nitroaniline	2.5<br>
2-Methyl-4-nitroaniline	1.04<br><br>
Methyl 4-aminobenzoate 1.5<br>
4-Aminobenzophenone 2.2<br>
2-Nitroaniline	-0.23<br>
In the reaction, it is advantageous to add an acid, for example a Bron-<br>
sted acid, such as hydrochloric acid, or a Lewis acid, or alternatively to<br>
add 2,2-dichlorodioxene, a compound which, as is known from the<br>
literature (R. K. Summerbell, H. E. Lunk, J. Am. Chem. Soc. 79, p.<br>
4802, 1957), readily dissociates into hydrogen chloride and 2-chloro-<br>
dioxene. The reaction can be carried out in many solvents, for example<br>
toluene, acetonitrile, dioxane, but also in mass, i.e. without solvent.<br>
Typical reaction temperatures are 0 to 150°C, generally around 80°C,<br>
for example between 70 and 90°C.<br>
The advantage of this process lies in the ready accessibility of<br>
2-chlorodioxene or 2,2-dichlorodioxane.<br><br>
The preparation of 2,3-dichlorodioxane is described, for example, in<br>
M. lyoda et al, Heterocycles, 54, p. 833, 2001. The thermal elimination<br>
of hydrogen chloride is described in US 2 756 240. This method gives<br>
2-chlorodioxene, which is contaminated with a certain proportion of 2,2-<br>
dichlorodioxane (typically 5 to 50%).<br>
N. V. Kuznetsov, I. I. Krasavtsev, Sov. Prog. Chem. (Engl. Transl.) 44,<br>
p. 77, 1987, describe methods for the preparation of 2-chlorodioxene<br>
from 2,3-dichlorodioxane using sodium hydroxide.<br><br><br>
The cyclisation of chloroethoxyacetamides to give morpholinones has<br>
hitherto only been described in two publications, in DE 922613 and<br>
L. Fumagalii et al. Pharmazie 30, 78 (1975).<br>
Both cases involve triiodobenzoic acid and triiodophenylalkanoic acid<br>
derivatives.<br><br>
However, this process is only suitable for substrates which are water-<br>
soluble, as in the above documents, in which R always contains a free<br>
carboxyl group.<br>
We have found that chloroethoxyacetamides can preferably be cyclised<br>
to give morpholinones using weak bases, such as, for example, caesium<br>
carbonate or potassium carbonate, in a suitable solvent, such as,<br>
for example, acetonitrile.<br>
Above and below, A denotes alkyl, is unbranched (linear) or branched, and<br>
has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. A preferably denotes methyl,<br>
furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl,<br>
furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethyl-<br>
propyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-,<br>
2,2- , 2,3-or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl,<br>
1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, furthermore pref-<br>
erably, for example, trifluoromethyl.<br><br>
A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C<br>
atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl,<br>
tert-butyl, pentyl, hexyl ortrifluoromethyl.<br>
A' preferably denotes alkyl having 1, 2, 3,4, 5 or 6 C atoms, preferably<br>
methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl,<br>
hexyl or trifluoromethyl.<br>
Cycloalkyl has 3-7 C atoms and preferably denotes cyclopropyl, cyclobutyl,<br>
cyclopentyl or cylohexyl.<br>
Hal preferably denotes F, CI or Br, but also I.<br>
R1 preferably denotes NO2, CN, COOH, COOR3, COR3 or CI.<br>
R2 preferably denotes H, Hal or A.<br>
R3 preferably denotes H, A' or -[C(R5)2]n-Ar.<br>
R4 preferably denotes A.<br>
Ar denotes, for example, phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl,<br>
o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butyl-<br>
phenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-<br>
aminophenyl, o-, m- or p-(N-methylamino)phenyl, o-, m- or p-(N-methyl-<br>
aminocarbonyl)phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-methoxy-<br>
phenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m-<br>
or p-(N,N-dimethylamino)phenyl, o-, m- or p-(N,N-dimethylaminocarbonyl)-<br>
phenyl, o-, m- or p-(N-ethylamino)phenyl, o-, m- or p-(N.N-diethylamino)-<br>
phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-<br>
chlorophenyl, o-, m- or p-(methylsulfonamido)phenyl, o-, m- or p-(methyl-<br>
sulfonyl)phenyl, furthermore preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-di-<br>
fluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-,<br>
2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-<br>
dimethoxyphenyl, 3-nitro-4-chlorophenyl, 3-amino-4-chloro-, 2-amino-3-<br><br>
chloro-, 2-amino-4-chloro-, 2-amino-5-chloro- or 2-amino-6-chlorophenyl,<br>
2-nitro-4-N,N-dimethylamino- or 3-nitro-4-N,N-dimethylaminophenyl, 2,3-<br>
diaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-<br>
trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-di-<br>
chloro-4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl,<br>
2,5-difluoro-4-bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-meth-<br>
oxyphenyl, 3-chloro-4-acetamidophenyl, 3-fluoro-4-methoxyphenyl, 3-<br>
amino-6-methylphenyl, 3-chloro-4-acetamidophenyl or 2,5-dimethyl-4-<br>
chlorophenyl.<br>
Ar preferably denotes, for example, phenyl which is unsubstituted or<br>
mono-, di- or trisubstituted by Hal, A, OR5, SO2A, COOR5 or CN.<br>
Ar particularly preferably denotes, for example, phenyl which is unsubstituted<br>
or mono- or disubstituted by Hal, A, OA, SO2A, SO2NH2, COOR5 or<br>
CN, such as, for example, phenyl, 2-methylsulfonylphenyl,<br>
2-aminosulfonylphenyl, 2-, 3- or 4-chlorophenyl, 4-methylphenyl,<br>
4-bromophenyl, 3-fluoro-4-methoxyphenyl, 4-trifluoromethoxyphenyl,<br>
4-ethoxyphenyl, 2-methoxyphenyl, 3-cyanophenyl or 4-ethoxycarbonyl-<br>
phenyl.<br>
Ar very particularly preferably denotes unsubstituted phenyl.<br>
Het is unsubstituted or mono- or disubstituted by Hal, A, OR5, N(R5)2, NO2,<br>
CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2, S(O)nA<br>
and/or carbonyl oxygen (=O) and denotes, for example, 2- or 3-furyl, 2- or<br>
3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazo-<br>
lyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or<br>
5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore<br>
preferably 1,2,3-triazol-i-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-<br>
tetrazolyl, 1,2,3-oxadiazol-4- or-5-yl, 1,2,4-oxadiazol-3- or-5-yl, 1,3,4-<br>
thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl,<br>
3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or<br>
5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyra-<br><br>
zolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7- berizisoxazolyl, 2-,<br>
4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or<br>
7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-,<br>
7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or<br>
8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-<br>
oxazinyl, furthermore preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-<br>
yl, 2,1,3-benzothiadiazol-4- or -5-yl or 2,1,3-benzoxadiazol-5-yl.<br>
The heterocyclic radicals may also be partially or fully hydrogenated.<br>
Het can thus also denote, for example, 2,3-dihydro-2-, -3-, -4- or -5-furyl,<br>
2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl,<br>
tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or-5-pyrrolyl, 2,5-<br>
dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-,<br>
-2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-<br>
1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2,3,4-tetra-<br>
hydro-1-, -2-, -3-, -4-, -5- or-6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or<br>
4-morpholinyl, tetrahydro-2-, -3- or-4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-,<br>
-4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-<br>
pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-,<br>
-6-, -7- or -8-quinolyl, 1,2,3-tetrahydro-1-,-2,-3-, -4-, -5-, -6-, -7- or -8-isoquinolyl,<br>
2-, 3-, 5-, 6-, 7- or 8- 3,4-dihydro-2H-benzo-1,4-oxazinyl, further-<br>
more preferably 2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl,<br>
2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylene-<br>
dioxy)phenyl, 2,3-dihydrobenzofuran-5- or 6-yl, 2,3-(2-oxomethylenedioxy)-<br>
phenyl or alternatively 3,4-dihydro-2H-1,5-benzodioxepin-6- or -7-yl,<br>
furthermore preferably 2,3-dihydrobenzofuranyl or 2,3-dihydro-2-oxo-<br>
furanyl.<br>
n preferably denotes 0 or 1.<br>
m preferably denotes 0, 1 or 2.<br>
The invention preferably relates to a process according to Claim 1 for the<br>
preparation of compounds of the formula I in which<br><br>
R1 denotes NO2, CN, COOR3, COR3 or CI,<br>
R2 denotes H, Hal or A.<br>
Preference is furthermore given to a process according to Claim 1 or 2 for<br>
the preparation of compounds of the formula I in which<br>
R1 denotes NO2, CN, COOR3, CON(R3)2, COR3, SO2R4, SO2N(R3)2,<br>
CF3, F or CI,<br>
R2 denotes H, Hal or A,<br>
R3 denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het.<br>
Preference is furthermore given to a process according to Claim 1 for the<br>
preparation of compounds of the formula I in which Ar denotes phenyl.<br>
Preference is furthermore given to a process for the preparation of com-<br>
pounds of the formula I in which R4 denotes A.<br>
Preference is furthermore given to a process for the preparation of com-<br>
pounds of the formula I in which<br>
R1	denotes NO2, CN, COOR3, CON(R3)2, COR3, CF3, F or CI,<br>
R2	denotes H, Hal or A1,<br>
R3	denotes H, A1 or -[C(R5)2]n-Ar,<br>
Ar	denotes phenyl,<br>
R5	denotes H or A',<br>
A1	denotes unbranched or branched alkyl having 1-6 C atoms,<br>
Hal	denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2.<br>
Very particular preference is given to a process according to Claim 1 for<br>
the preparation of compounds selected from the group<br>
4-(4-nitrophenyl)-3-oxomorpholine,<br>
4-(3-nitrophenyl)-3-oxomorpholine,<br>
4-(2-nitrophenyl)-3-oxomorpholine,<br><br>
2-methyl-4-(4-nitrophenyl)-3-oxomorpholine,<br>
4-(4-methoxycarbonylphenyl)-3-oxomorpholine,<br>
4-(4-benzoylphenyl)-3-oxomorpholine.<br>
Preference is furthermore given to a process according to one or more of<br>
Claims 1-6 for the preparation of compounds of the formula I in which the<br>
amine of the formula II has a pKa value ≤ 3.<br>
The compounds of the formula I can preferably be obtained by, in a first<br>
step a), reacting compounds of the formula II with 5-chloro-2,3-dihydro-<br>
1,4-dioxin to give a compound of the formula III.<br>
The reaction is generally carried out in an inert solvent, but can also be<br>
carried out without solvent in mass.<br>
It is advantageous to add an acid, for example a Bronsted acid, such as<br>
hydrochloric acid, or a Lewis acid, or alternatively to add 2,2-dichloro-<br>
dioxene, a compound which, as is known from the literature (R. K. Sum-<br>
merbell, H. E. Lunk, J. Am. Chem. Soc. 79, p. 4802, 1957), readily dissociates<br>
into hydrogen chloride and 2-chlorodioxene.<br>
Depending on the conditions used, the reaction time is between a few<br>
minutes and 14 days, preferably between one and ten hours, the reaction<br>
temperature is between about 0° and 150°, normally between 20° and<br>
130°, preferably between 60° and 110°, very particularly preferably<br>
between 70° and 90°C.<br>
Suitable inert solvents are, for example, water; hydrocarbons, such as<br>
hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydro-<br>
carbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachlo-<br>
ride, chloroform or dichloromethane; alcohols, such as methanol, ethanol,<br>
isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl<br>
ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers,<br>
such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or<br>
ethyl glycol), ethylene glycol dimethyl ether (diglyme); ketones, such as<br><br>
acetone or butanone; amides, such as acetamide, dimethylacetamide or<br>
dimethylformamide (DMF); nitrites, such as acetonitrile; sulfoxides, such as<br>
dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as<br>
formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene;<br>
esters, such as ethyl acetate, or mixtures of the said solvents.<br>
Particular preference is given to acetonitrile.<br>
In a second step b), compounds of the formula III are cyclised to give the<br>
compounds of the formula I.<br>
The reaction is generally carried out in an inert solvent, preferably in the<br>
presence of an alkali or alkaline earth metal hydroxide, carbonate or<br>
bicarbonate. Very particular preference is given to weak bases, such as<br>
caesium carbonate or potassium carbonate.<br>
Depending on the conditions used, the reaction time is between a few<br>
minutes and 14 days, preferably between one and twenty hours, the reaction<br>
temperature is between about 0° and 150°, normally between 0° and<br>
90°, preferably between 10° and 70°, particularly preferably between 20°<br>
and 50°C.<br>
Suitable inert solvents are, for example, hydrocarbons, such as hexane,<br>
petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons,<br>
such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride,<br>
chloroform or dichloromethane; alcohols, such as methanol, ethanol, iso-<br>
propanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl<br>
ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers,<br>
such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or<br>
ethyl glycol), ethylene glycol dimethyl ether (diglyme); ketones, such as<br>
acetone or butanone; amides, such as acetamide, dimethylacetamide or<br>
dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as<br>
dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as<br>
formic acid or acetic acid; nitro compounds, such as nitromethane or nitro-<br><br>
benzene; esters, such as ethyl acetate, or mixtures of the said solvents,<br>
particular preference is given to acetonitrile.<br>
Process steps a) and b) can also be carried out as a one-pot reaction.<br>
When the amine and 2-chlorodioxene have reacted completely, the temperature<br>
of the solution is lowered and an excess of alkali metal carbonate<br>
(typically 1.5 to 4 equivalents) is added and the reaction mixture is stirred<br>
until conversion is complete.<br>
A base of the formula I can be converted into the associated acid-addition<br>
salt using an acid, for example by reaction of equivalent amounts of the<br>
base and the acid in an inert solvent, such as ethanol, followed by evapo-<br>
ration. Suitable acids for this reaction are, in particular, those which give<br>
physiologically acceptable salts. Thus, it is possible to use inorganic acids,<br>
for example sulfuric acid, nitric acid, hydrohalic acids, such as hydrochloric<br>
acid or hydrobromic acid, phosphoric acids, such as orthophosphoric acid,<br>
sulfamic acid, furthermore organic acids, in particular aliphatic, alicyclic,<br>
araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic<br>
or sulfuric acids, for example formic acid, acetic acid, propionic acid, pivalic<br>
acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric<br>
acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic<br>
acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or<br>
ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonic acid,<br>
benzenesulfonic acid, p-toluenesulfonic acid, naphthalenemono- and<br>
-disulfonic acids, laurylsulfuric acid. Salts with physiologically unacceptable<br>
acids, for example picrates, can be used for the isolation and/or purification<br>
of the compounds of the formula I.<br>
On the other hand, compounds of the formula I can be converted into the<br>
corresponding metal salts, in particular alkali metal or alkaline earth metal<br>
salts, or into the corresponding ammonium salts using bases (for example<br><br>
sodium hydroxide, potassium hydroxide, sodium carbonate or potassium<br>
carbonate).<br>
It is also possible to use physiologically acceptable organic bases, such<br>
as, for example, ethanolamine.<br>
The invention also relates to the intermediate compounds of the formula III<br><br>
R1 denotes NO2 or CN,<br>
R2 denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2,<br>
NR3COA, NR3CON(R3)2, NR3COOR3, NR3SO2A, -[C(R5)2]n-Ar,<br>
-[C(R5)2]n-Het, -[C(R5)2]n-cycloalkyl, COR3, SO2N(R3)2 or SO2R4,<br>
R3 denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R4 denotes A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R5 denotes H or A1,<br>
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubsti-<br>
tuted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2,<br>
NR5COA, NR5SO2A, COR5, SO2N(R5)2 or S(O)nA,<br>
Het denotes a mono- or bicyclic saturated, unsaturated or aromatic<br>
heterocycle having 1 to 4 N, O and/or S atoms which is unsubsti-<br>
tuted or mono- or disubstituted by Hal, A, OR5, N(R5)2, NO2, CN,<br>
COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2, S(O)nA<br>
and/or carbonyl oxygen (=0),<br>
A1 denotes unbranched or branched alkyl having 1-6 C atoms,<br><br>
A	denotes unbranched, branched or cylic alkyf having 1-12 C atoms,<br>
in which one or two CH2 groups may be replaced by O or S atoms<br>
and/or by -CH=CH- groups and/or in addition 1-7 H atoms may be<br>
replaced by F,<br>
Hal denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
m denotes 0, 1, 2, 3 or 4,<br>
and salts thereof.<br>
The intermediate compounds are important for the preparation of the compounds<br>
of the formula I.<br>
The preferred meanings of the radicals correspond to those as indicated<br>
above, unless expressly stated otherwise.<br>
The invention also relates to the intermediate compounds according to<br>
Claim 15 in which<br>
R1 denotes NO2 or CN,<br>
R2 denotes H, Hal or A,<br>
and salts thereof.<br>
Preference is furthermore given to intermediate compounds according to<br>
Claim 15 in which<br>
R1 denotes NO2 or CN,<br>
R2 denotes H, Hal or A,<br>
R3 denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
and salts thereof.<br>
Preference is furthermore given to intermediate compounds according to<br>
Claim 15, 16 or 17 in which<br>
Ar denotes phenyl,<br>
and salts thereof.<br><br>
Preference is furthermore given to intermediate compounds according to<br>
one or more of Claims 15-18 in which<br>
R4 denotes A,<br>
and salts thereof.<br>
Particular preference is given to intermediate compounds according to one<br>
or more of Claims 15-19 in which<br>
R1 denotes NO2 or CN,<br>
R2 denotes H, Hal or A1,<br>
R3 denotes H, A' or -[C(R5)2]n-Ar,<br>
Ar denotes phenyl,<br>
R5 denotes H or A1,<br>
A1 denotes unbranched or branched alkyl having 1-6 C atoms,<br>
Hal denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
m denotes 0, 1 or 2,<br>
and salts thereof.<br>
Particular preference is given to intermediate compounds according to<br>
Claim 20 in which<br>
R1 denotes NO2,<br>
R2 denotes H, Hal or A1,<br>
R3 denotes H, A1 or -[C(R5)2]n-Ar,<br>
Ar denotes phenyl,<br>
R5 denotes H or A1,<br>
A1 denotes unbranched or branched alkyl having 1-6 C atoms,<br>
Hal denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
m denotes 0, 1 or 2,<br>
and salts thereof.<br>
The invention also relates to a process for the preparation of intermediate<br>
compounds of the formula III<br><br><br>
R1 denotes NO2, CN, COOR3, CON(R3)2, COR3, SO2R4, SO2N(R3)2,<br>
CF3, For CI,<br>
R2 denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2,<br>
NR3COA, NR3CON(R3)2, NR3COOR3, NR3SO2A, -[C(R5)2]n-Ar,<br>
-[C(R5)2]n-Het, -[C(R5)2]n-cycloalkyl, COR3, SO2N(R3)2 or SO2R4,<br>
R3 denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R4 denotes A, -[C(R5)2]n-Ar or -[C(R5)a]n-Het,<br>
R5 denotes H or A1,<br>
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubsti-<br>
tuted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2,<br>
NR5COA, NR5SO2A, COR5, SO2N(R5)2 or S(O)nA,<br>
Het denotes a mono- or bicyclic saturated, unsaturated or aromatic<br>
heterocycle having 1 to 4 N, O and/or S atoms which is unsubsti-<br>
tuted or mono- or disubstituted by Hal, A, OR5, N(R5)2, NO2, CN,<br>
COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2, S(O)nA<br>
and/or carbonyl oxygen (=O),<br>
A1 denotes unbranched or branched alkyl having 1-6 C atoms,<br>
A	denotes unbranched, branched or cylic alkyl having 1-12 C atoms,<br>
in which one or two CH2 groups may be replaced by O or S atoms<br>
and/or by -CH=CH- groups and/or in addition 1-7 H atoms may be<br>
replaced by F,<br>
Hal denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br><br>
m denotes 0, 1, 2, 3 or 4,<br>
and salts thereof, characterised in that<br>
a) a compound of the formula II<br>
X-NH2	II<br>
in which<br>
X has the meaning indicated above,<br>
is reacted with 5-chloro-2,3-dihydro-1,4-dioxin<br><br>
and<br>
the compound of the formula III is optionally converted into its salt.<br>
The conditions of the process, in particular the preferred ones, are the<br>
same as indicated under the process for the preparation of the compound<br>
of the formula I.<br>
The preferred meanings of the radicals correspond to those as indicated<br>
above, unless expressly stated otherwise.<br>
Preference is given to a process according to Claim 22 for the preparation<br>
of intermediate compounds of the formula III<br>
in which<br>
R1 denotes NO2 or CN,<br>
R2 denotes H, Hal, A, OR3, N(R3)2l NO2, CN, COOR3, CON(R3)2,<br>
NR3COA, NR3CON(R3)2, NR3COOR3, NR3SO2A,<br>
-[C(R5)2]n-Ar, -[C(R5)2]n-Het, -[C(R5)2]n-cycloalkyl, COR3, SO2N(R3)2<br>
or SO2R4,<br>
R3 denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R4 denotes A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br><br>
R5 denotes H or A1,<br>
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubsti-<br>
tuted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2l<br>
NR5COA, NR5SO2A, COR5, SO2N(R5)2 or S(O)nA,<br>
Het denotes a mono- or bicyclic saturated, unsaturated or aromatic<br>
heterocycle having 1 to 4 N, O and/or S atoms which is unsubsti-<br>
tuted or mono- or disubstltuted by Hal, A, OR5, N(R5)2, NO2, CN,<br>
COOR5, CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2, S(O)nA<br>
and/or carbonyl oxygen (=0),<br>
A1 denotes unbranched or branched alkyl having 1-6 C atoms,<br>
A	denotes unbranched, branched or cylic alkyl having 1-12 C atoms,<br>
in which one or two CH2 groups may be replaced by O or S atoms<br>
and/or by -CH=CH- groups and/or in addition 1-7 H atoms may be<br>
replaced by F,<br>
Hal denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
m denotes 0, 1, 2, 3 or 4.<br>
Preference is furthermore given to a process according to Claim 23 for the<br>
preparation of intermediate compounds of the formula III<br>
in which<br>
R1 denotes NO2 or CN,<br>
R2 denotes H, Hal or A.<br>
Preference is furthermore given to a process according to Claim 23 for the<br>
preparation of intermediate compounds of the formula III<br>
in which<br>
R1 denotes NO2 or CN,<br>
R2 denotes H, Hal or A,<br>
R3 denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het.<br><br>
Preference is furthermore given to a process according to Claim 23 for the<br>
preparation of intermediate compounds of the formula III<br>
in which<br>
Ar denotes phenyl.<br>
Preference is also given to a process according to Claim 23 for the preparation<br>
of intermediate compounds of the formula III<br>
in which<br>
R4 denotes A.<br>
Particular preference is given to a process according to Claim 23 for the<br>
preparation of intermediate compounds of the formula III<br>
in which<br>
R1 denotes NO2 or CN,<br>
R2 denotes H, Hal or A",<br>
R3 denotes H, A1 or -[C(R5)2]n-Ar,<br>
AΓ denotes phenyl,<br>
R5 denotes H or A',<br>
A1 denotes unbranched or branched alkyl having 1-6 C atoms,<br>
Hal denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
m	denotes 0, 1 or 2.<br>
Above and below, all temperatures are indicated in °C.<br>
Mass spectrometry (MS): El (electron impact ionisation) M+;<br>
ESI (electrospray ionisation) (M+H)+;<br>
FAB (fast atom bombardment) (M+H)+<br>
Example 1<br>
4-(4-Nitrophenyl)-3-oxomorpholine<br><br>
The preparation is carried out analogously to the following scheme:<br><br>
1.1	without solvent:<br>
1.53 g of a mixture of 2-chlorodioxene and 2,2-dichlorodioxane (molar<br>
ratio 1:1) are added to 1.00 g (7.24 mmol) of 4-nitroaniline, and the<br>
mixture is heated to 80°C with stirring. A solid brown mass forms within<br>
one hour and becomes liquid again and crystallises within the following<br>
12 hours. The crude product is recrystallised from ethanol with addition<br>
of water, giving 1.80 g of 2-(2-chloroethoxy)-N-(4-nitrophenyl)acetamide<br>
("A1") as yellowish crystals, m.p. 101-102°C. 1H-NMR (d6-DMSO):<br>
 = 3.82 (m; 4H), 4.23 (s; 2H), 7.91 (d, J = 9 Hz, 2H), 8.23 (d, J = 9 Hz,<br>
2H), 10.34 (s, 1H).<br>
1.2	in acetonitrile:<br>
310 mg of a mixture of 2-chlorodioxene and 2,2-dichlorodioxane (molar<br>
ratio 1:1) are added to a solution of 276 mg (2.00 mmol) of 4-nitroaniline<br>
in 2 ml of acetonitrile, and the solution is heated at 80°C with stirring for<br>
18 hours. The reaction mixture is evaporated, and the residue is recrystallised<br>
from ethanol/water: 360 mg of "A1" as yellowish crystals.<br>
1.3	1 kg of "A1" is dissolved in 5 litres of acetonitrile at room temperature,<br>
835 g of potassium carbonate are added, and the mixture is stirred at<br><br>
this temperature for 18 hours. The mixture is warmed to 50° and worked<br>
up analogously to Example 6, giving 4-(4-nitrophenyl)-3-oxomorpholine<br>
("A2"), m.p. 150-152°.<br>
Example 2<br>
4-(4-Nitro-2-methvlphenvl)-3-oxomorpholine<br>
1.05 g of a mixture of 2-chlorodioxene and 2,2-dichlorodioxane (molar<br>
ratio 1:1) are added to a solution of 1.10 g (7.24 mmol) of 2-methyl-4-<br>
nitroaniline in 20 ml of THF, and the mixture is heated to the boil. The<br>
solvent is distilled off, and the residue, a brown viscous liquid, is heated<br>
at 80°C for 18 hours. After cooling, the residue is recrystallised from<br>
toluene/tert-butyl methyl ether: 1.50 g of 2-(2-chloroethoxy)-N-(2-methyl-<br>
4-nitrophenyl)acetamide as yellowish crystals, m.p. 113-114°C. 1H-NMR<br>
(d6-DMSO): 5 = 2.35 (s; 3H), 3.82 (m; 4H), 4.23 (s; 2H), 8.05 (d,<br>
J = 8Hz, 1 H) 8.09 (dd, J = 9 Hz, J = 1 Hz, 1H), 8.16 (d, J = 1 Hz, 1H),<br>
9.33 (s, 1H).<br>
The cyclisation is carried out analogously to 1.3,<br>
giving 4-(4-nitro-2-methylphenyl)-3-oxomorpholine, ESI 237.<br>
Example 3<br>
4-(2-Nitrophenvl)-3-oxomorpholine<br>
1.12 g of a mixture of 2-chlorodioxene and 2,2-dichlorodioxane (molar ratio<br>
89:11) are added to 1.12 g (8.12 mmol) of 2-nitroaniline, and the mixture is<br>
heated to 80°C with stirring. A viscous liquid forms, which is stirred for 3<br>
hours. On cooling to room temperature, the product crystallises: 2.1 g of<br>
2-(2-chloroethoxy-N-(2-nitrophenyl)acetamide as yellowish crystals. 1H-<br>
NMR (d6-DMSO): δ = 3.84 (m; 4H), 4.25 (s; 2H), 7.35 (t, J = 8 Hz, 1H),<br><br>
7.77 (t, J = 8 Hz, 1H), 8.14 (d, J = 8 Hz, 1H), 8.30 (d, J = 8 Hz, 1H), 10.74<br>
(s, 1H).<br>
The cyclisation is carried out analogously to 1.3,<br>
giving 4-(2-nitrophenyl)-3-oxomorpholine, ESI 223.<br>
Example 4<br>
4-(4-Cyanophenyl)-3-oxomorpholine<br>
A mixture of 959 mg (8.12 mmol) of 4-aminobenzonitrile and 1.12 g of a<br>
mixture of 2-chlorodioxene and 2,2-dichlorodioxane (molar ratio 89:11) is<br>
heated at 80°C with stirring for 18 hours. On cooling to room temperature,<br>
the product crystallises: 1.9 g of 2-(2-chloroethoxy)-N-(4-cyanophenyl)-<br>
acetamide as yellowish crystals. 1H-NMR (d6-DMSO): δ = 3.82 (m; 4H),<br>
4.19 (s; 2H), 7.78 (d, J = 8 Hz, 2H), 7.85 (d, J = 8 Hz, 2H), 10.22 (s, 1H).<br>
The cyclisation is carried out analogously to 1.3,<br>
giving 4-(4-cyanophenyl)-3-oxomorpholine, ESI 203.<br>
Example 5<br>
4-(4-Methoxycarbonylphenyl)-3-oxomorpholine<br>
A mixture of 1.23 mg (8.12 mmol) of methyl 4-aminobenzoate and<br>
1.12 g of a mixture of 2-chlorodioxene and 2,2-dichlorodioxane (molar<br>
ratio 89:11) is heated at 80°C with stirring for 18 hours. On cooling to<br>
room temperature, the product crystallises: 2.2 g of methyl 4-[2-(2-<br>
chloroethoxy)acetylaminojbenzoate as yellowish crystals. 1H-NMR<br>
(d6-DMSO): δ = 3.82 (m; 7H), 4.20 (s; 2H), 7.82 (d, J = 8 Hz, 2H), 7.93<br>
(d, J = 8 Hz, 2H), 10.15 (s, 1H).<br>
The cyclisation is carried out analogously to 1.3,<br>
giving 4-(4-methoxycarbonylphenyl)-3-oxomorpholine, ESI 236.<br><br>
Example 6<br>
One-pot reaction for the preparation of "A2"<br>
6.40 g of 2-chlorodioxene (contains 6% of 2,2-dichlorodioxane) are<br>
added to a solution of 6.00 g (24.9 mmol) of 4-nitroaniline in 40 ml of<br>
acetonitrile, and the mixture is stirred at 80°C for 18 hours. The reaction<br>
solution is cooled to 40ºC, 18.0 g (130 mmol) of potassium carbonate<br>
are added, and the mixture is stirred at this temperature for 14 hours.<br>
The reaction mixture is filtered, the residue is washed well with acetonitrile,<br>
and the filtrate is evaporated. The residue is recrystallised from<br>
acetonitrile: 8.2 g of brownish crystals ("A2"), m.p. 150-152°C. 1H-NMR<br>
(d6-DMSO): δ = 3.86 (t, J = 5 Hz; 2H), 4.02 (t, J = 5 Hz; 2H), 4.28 (s;<br>
2H), 7.77 (d, J = 9 Hz, 2H), 8.28 (d, J = 9 Hz, 2H).<br>
Example 7<br>
4-(3-Nitrophenvl)-3-oxomorpholine<br>
A mixture of 1.12 g (8.12 mmol) of 3-nitroaniline and 1.11 g of 2-chlorodioxene<br>
(contains 6% of 2,2-dichlorodioxane) is heated at 80°C with<br>
stirring for 24 hours, giving 2.1 g of 2-(2-chloroethoxy)-N-(3-nitrophenyl)-<br>
acetamide as brownish oil. ESI 259.<br>
The cyclisation is carried out analogously to 1.3,<br>
giving 4-(3-nitrophenyl)-3-oxomorpholine, ESI 223.<br>
Example 8<br>
4-(4-Benzoylphenyl)-3-oxomorpholine<br>
A mixture of 1.60 g (8.12 mmol) of 4-aminobenzophenone and 1.11 g of<br>
2-chlorodioxene (contains 6% of 2,2-dichlorodioxane) is heated at 80°C<br><br>
with stirring for 24 hours, giving 2.6 g of N-(4-benzoylphenyl)-2-(2-<br>
chloroethoxy)acetamide as brown oil. ESI 318.<br>
The cyclisation is carried out analogously to 1.3,<br>
giving 4-(4-benzoylphenyl)-3-oxomorpholine, ESI 282.<br><br>
A mixture of 12.0 g (108 mmol) of 3-fluoraniline and 16 g of 2-chloro-<br>
dioxene (contains 6% of 2,2-dichlorodioxane) is heated at 100°C for<br>
24 hours. The mixture is allowed to cool, and excess 2-chlorodioxene is<br>
removed under reduced pressure, giving 25 g of 2-(2-chloroethoxy)-N-<br>
(3-fluorophenyl)acetamide as brown oil; ESI 232. This oil is dissolved in<br>
400 ml of acetonitrile, and 84.7 g (260 mmol) of caesium carbonate are<br>
added. The suspension formed is stirred at room temperature for<br>
18 hours. The reaction mixture is filtered, and the filtrate is evaporated,<br>
giving 21.0 g of 4-(3-fluorophenyl)morpholin-3-one as brown oil; ESI<br>
196. 1H-NMR (d6-DMSO): δ = 3.77 (t, J = 5 Hz; 2H), 3.97 (t, J = 5 Hz;<br>
2H), 4.23 (s; 2H), 7.11 (dddd, Ji = 8 Hz, J2 = 8 Hz, J3 = 2 Hz, J4 =<br>
0.5 Hz, 1H), 7.26 (ddd, J1 = 8 Hz, J2 = 2 Hz, J3 = 0.5 Hz, 1H), 7.34 (ddd,<br>
J1 = 10 Hz, J2 = 2 Hz, J3 = 2 Hz, 1H), 7.45 (ddd, J1 = 8 Hz, J2 = 8 Hz,<br>
J3 = 7Hz, 1H).<br><br><br>
12.8 g of 2-chlorodioxene (contains 6% of 2,2-dichlorodioxane) are<br>
added to a solution of 10.0 g (65.7 mmol) of 3-methyl-4-nitroaniline in<br>
250 ml of acetonitrile, and the mixture is stirred at 80°C for 66 hours.<br>
The reaction solution is cooled to room temperature, 42.8 g (131 mmol)<br>
of caesium carbonate are added, and the mixture is stirred at room<br>
temperature for 18 hours. The reaction mixture is filtered, the residue is<br>
washed well with acetonitrile, and the filtrate is evaporated. The residue<br>
is recrystallised from a little acetonitrile, giving 12.8 g (83%) of 4-(3-<br>
methyl-4-nitrophenyl)morpholin-3-one as yellowish solid. ESI 236.<br>
1H-NMR (d6-DMSO): δ = 2.54 (s; 2H), 5 = 3.82 (t, J = 5 Hz; 2H), 4.00 (t,<br>
J = 5 Hz; 2H), 4.25 (s; 2H), 7.57 (m; 2H), 8.04 (d, J. = 8 Hz; 1H).<br>
4-(2-Chloro-5-fluoro-4-nitrophenyl)-3-oxomorpholine is obtained<br>
analogously<br><br><br><br><br>
WE CLAIM :	Patent Claims<br><br>
1. Process for the preparation of compounds of N-arylmorpholine the formula I<br><br>
R1	denotes NO2, CN, COOR3, CON(R3)2, COR3, SO2R4,<br>
SO2N(R3)2, CF3, F or CI,<br>
R2	denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3,<br>
CON(R3)2, NR3COA, NR3CON(R3)2, NR3COOR3,<br>
NR3SO2A, -[C(R5)2]n-Ar, -[C(R5)2]n-Het, -[C(R5)2]n-<br>
cycloalkyl, COR3, SO2N(R3)2 or SO2R4,<br>
R3	denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R4	denotes A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R5	denotes H or A',<br>
Ar	denotes phenyl which is unsubstituted or mono-, di- or<br>
trisubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5,<br>
CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2 or<br>
S(O)nA,<br>
Het	denotes a mono- or bicyclic saturated, unsaturated or<br>
aromatic heterocycle having 1 to 4 N, O and/or S atoms<br>
which is unsubstituted or mono- or disubstituted by Hal,<br>
A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA,<br>
NR5SO2A, COR5, SO2N(R5)2, S(O)nA and/or carbonyl<br>
oxygen (=0),<br><br>
A'	denotes unbranched or branched alkyl having 1-6 C<br>
atoms,<br>
A	denotes unbranched, branched or cylic alkyl having<br>
1-12 C atoms, in which one or two CH2 groups may be<br>
replaced by O or S atoms and/or by -CH=CH- groups<br>
and/or in addition 1-7 H atoms may be replaced by F,<br>
Hal	denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
m	denotes 0, 1, 2, 3 or 4,<br>
and salts thereof, characterised in that<br>
a) a compound of the formula II<br>
X-NH2	II<br>
in which<br>
X has the meaning indicated above,<br>
is reacted with 5-chloro-2,3-dihydro-1,4-dioxin<br><br>
at a temperature between about OC and 150C ,for<br>
a period ranging from a few minutes and 14 days<br>
to give a compound of the formula III<br><br>
in which<br>
X has the meaning indicated above,<br>
at a temperature between about Ocand 150C tfor a<br>
period ranging from a few minutes and 14 days<br>
b) then a compound of the formula III is cyclised to give a compound<br>
of the formula I,<br><br>
and<br>
c) the latter is optionally converted into its salt<br>
by converting a base or acid of the formula I into one of its salts.<br>
2.	Process according to Claim 1 for the preparation of compounds of<br>
the formula I in which<br>
R1	denotes NO2, CN, COOR3, COR3 or CI,<br>
R2	denotes H, Hal or A,<br>
and salts thereof.<br>
3.	Process according to Claim 1 for the preparation of compounds of<br>
the formula I in which<br>
R1	denotes NO2, CN, COOR3, CON(R3)2, COR3, SO2R4,<br>
SO2N(R3)2, CF3, F or CI,<br>
R2	denotes H, Hal or A,<br>
R3	denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
and salts thereof.<br>
4.	Process according to Claim 1, 2 or 3 for the preparation of compounds<br>
of the formula I in which<br>
Ar	denotes phenyl,<br>
and salts thereof.<br>
5.	Process according to one or more of Claims 1-4 for the preparation of<br>
compounds of the formula I in which<br>
R4	denotes A,<br>
and salts thereof.<br>
6.	Process according to one or more of Claims 1-5 for the preparation of<br>
compounds of the formula I in which<br><br>
R1	denotes NO2, CN, COOR3, CON(R3)2, COR3, CF3, F or<br>
CI.<br>
R2	denotes H, Hal or A1,<br>
R3	denotes H, A1 or -[C(R5)2]n-Ar,<br>
Ar	denotes phenyl,<br>
R5	denotes H or A',<br>
A1	denotes unbranched or branched alkyl having 1-6 C<br>
atoms,<br>
Hal	denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
and salts thereof.<br>
7.	Process according to one or more of Claims 1-6 for the preparation of<br>
compounds of the formula I, in which the amine of the formula II has<br>
a pKa value 
8.	Process according to one or more of Claims 1-7, in which process<br>
steps a) and b) are carried out as a one-pot reaction.<br>
9. Process according to Claim 9, in which process step a) is carried out<br>
at a temperature between 70 and 90°C.<br>
10. Process according to one or more of Claims 1- 9, in which the<br>
cyclisation is carried out in an inert solvent or solvent mixture in the<br>
presence of an alkali or alkaline earth metal hydroxide, carbonate or<br>
bicarbonate.<br><br>
11 . Process according to one or more of Claims 1-10, in which the<br>
cyciisation is carried out in the presence of caesium carbonate or<br>
potassium carbonate.<br>
11. Process according to one or more of Claims 1-11, in which the process<br>
is carried out as a one-pot reaction in acetonitrile.<br>
13. Process according to one or more of Claims 1-12 for the preparation<br>
of compounds selected from the group<br>
4-(4-nitrophenyl)-3-oxomorpholine,<br>
4-(3-nitrophenyl)-3-oxomorpholine,<br>
4-(2-nitrophenyl)-3-oxomorpholine,<br>
2-methyl-4-(4-nitrophenyl)-3-oxomorpholine,<br>
4-(4-methoxycarbonylphenyl)-3-oxomorpholine,<br>
4-(4-benzoylphenyl)-3-oxomorpholine,<br>
and salts thereof.<br>
1H- Intermediate compounds of the formula III<br><br>
R1	denotes NO2 or CN,<br>
R2	denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3,<br>
CON(R3)2, NR3COA, NR3CON(R3)2, NR3COOR3,<br>
NR3SO2A, -[C(R5)2]n-Ar, -[C(R5)2]n-Het, -[C(R5)2]n-<br>
cycloalkyl, COR3, SO2N(R3)2 or SO2R4,<br><br>
R3	denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R4	denotes A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R5	denotes H or A",<br>
Ar	denotes phenyl which is unsubstituted or mono-, di- or<br>
trisubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5,<br>
CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2 or<br>
S(O)nA,<br>
Het	denotes a mono- or bicyclic saturated, unsaturated or<br>
aromatic heterocycle having 1 to 4 N, O and/or S atoms<br>
which is unsubstituted or mono- or disubstituted by Hal,<br>
A, OR5, N(R5)2, NO2l CN, COOR5, CON(R5)2, NR5COA,<br>
NR5SO2A, COR5, SO2N(R5)2, S(O)nA and/or carbonyl<br>
oxygen (=O),<br>
A1	denotes unbranched or branched alkyl having 1-6 C<br>
atoms,<br>
A	denotes unbranched, branched or cylic alkyl having<br>
1-12 C atoms, in which one or two CH2 groups may be<br>
replaced by O or S atoms and/or by -CH=CH- groups<br>
and/or in addition 1-7 H atoms may be replaced by F,<br>
Hal	denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
m	denotes 0, 1, 2, 3 or 4,<br>
and salts thereof.<br>
15. Intermediate compounds according to Claim 14 in which<br>
R1	denotes NO2 or CN,<br>
R2	denotes H, Hal or A,<br>
and salts thereof.<br>
16. Intermediate compounds according to Claim 14, in which<br>
R1	denotes NO2 or CN,<br>
R2	denotes H, Hal or A,<br><br>
R3	denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
and salts thereof.<br>
17. Intermediate compounds according to Claim 14, 15 or 16 in which<br>
Ar	denotes phenyl,<br>
and salts thereof.<br>
18. Intermediate compounds according to one or more of Claims 14-17 in<br>
which<br>
R4	denotes A,<br>
and salts thereof.<br>
19. Intermediate compounds according to one or more of Claims 14-18 in<br>
which<br>
R1	denotes NO2 or CN,<br>
R2	denotes H, Hal or A',<br>
R3	denotes H, A1 or -[C(R5)2]n-Ar,<br>
Ar	denotes phenyl,<br>
R5	denotes H or A1,<br>
A1	denotes unbranched or branched alkyl having 1-6 C<br>
atoms,<br>
Hal	denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
m	denotes 0, 1 or 2,<br>
and salts thereof.<br>
20. Intermediate compounds according to Claim 19 in which<br>
R1	denotes NO2,<br>
R2	denotes H, Hal or A1,<br>
R3	denotes H, A1 or -[C(R5)2]n-Ar,<br>
Ar	denotes phenyl,<br>
R5	denotes H or A1,<br><br>
A1	denotes unbranched or branched alkyl having 1-6 C<br>
atoms,<br>
Hal	denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
m	denotes 0, 1 or 2,<br>
and salts thereof.<br>
21. Process for the preparation of intermediate compounds of the<br>
formula III<br><br>
R1	denotes NO2, CN, COOR3, CON(R3)2, COR3, SO2R4,<br>
SO2N(R3)2, CF3, F or CI,<br>
R2	denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3,<br>
CON(R3)2, NR3COA, NR3CON(R3)2, NR3COOR3,<br>
NR3SO2A, -[C(R5)2]n-Ar, -[C(R5)2]n-Het, -[C(R5)2]n-<br>
cydoalkyl, COR3, SO2N(R3)2 or SO2R4,<br>
R3	denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R4	denotes A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R5	denotes H or A',<br>
Ar	denotes phenyl which is unsubstituted or mono-, di- or<br>
trisubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5,<br>
CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2 or<br>
S(O)nA,<br><br>
Het	denotes a mono- or bicyclic saturated, unsaturated or<br>
aromatic heterocycle having 1 to 4 N, O and/or S atoms<br>
which is unsubstituted or mono- or disubstituted by Hal,<br>
A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA,<br>
NR5SO2A, COR5, SO2N(R5)2, S(O)nA and/or carbonyi<br>
oxygen (=0),<br>
A'	denotes unbranched or branched alkyl having 1-6 C<br>
atoms,<br>
A	denotes unbranched, branched or cylic alkyl having<br>
1-12 C atoms, in which one or two CH2 groups may be<br>
replaced by O or S atoms and/or by -CH=CH- groups<br>
and/or in addition 1-7H atoms may be replaced by F,<br>
Hal	denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
m	denotes 0, 1, 2, 3 or 4,<br>
and salts thereof, characterised in that<br>
a) a compound of the formula II<br>
X-NH2	II<br>
in which<br>
X has the meaning indicated above,<br>
is reacted with 5-chloro-2,3-dihydro-1,4-dioxin<br><br>
the compound of the formula III is optionally converted into its salt.<br>
23, Process according to Claim 21 for the preparation of intermediate<br>
compounds of the formula III<br><br>
in which<br>
R1 denotes NO? or CN,<br>
R2 denotes H, Hal. A. OR3, N(R3)2, NO2, CN, COOR3, CON(R3)7.<br>
NR3COA, NR3CON(R3)2, NR3COOR3, NR3SO2A,<br>
-[C(R5)2]n-Ar. -[C(R5)2]n-Het, -[C(R5)2]n-cycloalkyl. COR3,<br>
SO2N(R3)2 or SO2R4,<br>
R3 denotes H. A, -fC(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R4 denotes A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R5 denotes H or A',<br>
Ar denotes phenyl which is unsubstituted or mono-, di- or<br>
trisubstituted by Hal. A, OR5, N(R5)2, NO2. CN. COOR5.<br>
CON(R5)2, NR5COA. NR5SO2A. COR5. SO2N(R5)2 or S(O)nA,<br>
Het denotes a mono- or bicyclic saturated, unsaturated or aromatic<br>
heterocycle having 1 to 4 N, O and/or S atoms which is<br>
unsubstituted or mono- or disubstituted by Hal, A, OR5,<br>
N(R5)2. NO2. CN. COOR5. CON(R5)2, NR5COA, NR5SO2A.<br>
COR5, SO2N(R5)2, S(O)nA and/or carbonyl oxygen (=O).<br>
A' denotes unbranched or branched alkyl having 1-6 C atoms,<br>
A	denotes unbranched, branched or cylic alkyl having 1-12 C<br>
atoms, in which one or two CH2 groups may be replaced by O<br>
or S atoms and/or by -CH=CH- groups and/or in addition 1-7<br>
H atoms may be replaced by F,<br>
Hal denotes F, CI. Br or I,<br>
n	denotes 0, 1 or 2.<br>
m	denotes 0, 1. 2, 3 or 4.<br>
23. Process according to Claim 23 for the preparation of intermediate<br>
compounds of the formula III<br>
in which<br>
R1	denotes NO2 or CN.<br>
R2	denotes H. Hal or A.<br><br>
24. Process according to Claim 22 for the preparation of intermediate<br>
compounds of the formula III<br>
in which<br>
R1	denotes NO2 or CN,<br>
R2	denotes H, Hal or A,<br>
R3	denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het.<br>
25. Process according to Claim 22 for the preparation of intermediate<br>
compounds of the formula III<br>
in which<br>
Ar denotes phenyl.<br>
26, Process according to Claim 22 for the preparation of intermediate<br>
compounds of the formula III<br>
in which<br>
R4 denotes A.<br>
27. Process according to Claim 22 for the preparation of intermediate<br>
compounds of the formula III<br>
in which<br>
R1	denotes NO2 or CN,<br>
R2	denotes H, Hal or A1,<br>
R3	denotes H, A1 or -[C(R5)2]n-Ar,<br>
Ar	denotes phenyl,<br>
R5	denotes H or A1,<br>
A1	denotes unbranched or branched alkyl having 1-6 C<br>
atoms,<br>
Hal	denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
m	denotes 0, 1 or 2.<br><br>
Process for the preparation of compounds of the formula I<br><br>
R1	denotes NO2, CN, COOR3, CONCR3)2, COR3, SO2R4,<br>
SO2N(R3)2, CF3, F or Cl,<br>
R2	denotes H, Hal, A, OR3, N(R3)2, NO2, CN, COOR3,<br>
CON(R3)2, NR3COA, NR3CON(R3)2, NR3COOR3,<br>
NR3SO2A, -[C(R5)2]n-Ar, -[C(R5)2]n-Het, -[C(R5)2]n-<br>
cycloalkyl, COR3, SO2N(R3)2 or SO2R4,<br>
R3	denotes H, A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R4	denotes A, -[C(R5)2]n-Ar or -[C(R5)2]n-Het,<br>
R5	denotes H or A',<br>
Ar	denotes phenyl which is unsubstituted or mono-, di- or<br>
trisubstituted by Hal, A, OR5, N(R5)2, NO2, CN, COOR5,<br>
CON(R5)2, NR5COA, NR5SO2A, COR5, SO2N(R5)2 or<br>
S(O)nA,<br>
Het	denotes a mono- or bicyclic saturated, unsaturated or<br>
aromatic heterocycle having 1 to 4 N, O and/or S atoms<br>
which is unsubstituted or mono- or disubstituted by Hal,<br>
A, OR5, N(R5)2, NO2, CN, COOR5, CON(R5)2, NR5COA,<br>
NR5SO2A, COR5, SO2N(R5)2, S(O)nA and/or carbonyl<br>
oxygen (=O),<br><br>
A'	denotes unbranched or branched alkyl having 1-6 C<br>
atoms,<br>
A	denotes unbranched, branched or cylic alkyl having<br>
1-12 C atoms, in which one or two CH2 groups may be<br>
replaced by O or S atoms and/or by -CH=CH- groups<br>
and/or in addition 1-7 H atoms may be replaced by F,<br>
Hal	denotes F, CI, Br or I,<br>
n	denotes 0, 1 or 2,<br>
m	denotes 0, 1, 2, 3 or 4,<br>
and salts thereof, characterised in that<br>
a) a compound of the formula II<br>
X-NH2	II<br>
in which<br>
X has the meaning indicated above,<br>
to give a compound of the formula III<br>
is reacted with 5-chloro-2,3-dihydro-1,4-dioxin<br><br><br>
in which<br>
X has the meaning indicated above,<br>
b) then a compound of the formula III is cyclised to give a compound<br>
of the formula I,<br><br>
c) the latter is optionally converted into its salt<br>
by converting a base or acid of the formula I into one of its salts.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDItS09MTlAtMjAwNi1GT1JNLTI3LTEucGRm" target="_blank" style="word-wrap:break-word;">42-KOLNP-2006-FORM-27-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDItS09MTlAtMjAwNi1GT1JNLTI3LnBkZg==" target="_blank" style="word-wrap:break-word;">42-KOLNP-2006-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLWNvcnJlc3BvbmRlbmNlLnBkZg==" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLWV4YW1pbmF0aW9uIHJlcG9ydC5wZGY=" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLWZvcm0gMS5wZGY=" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLWZvcm0gMi5wZGY=" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLWZvcm0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLWZvcm0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLWdwYS5wZGY=" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLXJlcGx5IHRvIGV4YW1pbmF0aW9uIHJlcG9ydC5wZGY=" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-reply to examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLXNwZWNpZmljYXRpb24ucGRm" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-specification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NDIta29sbnAtMjAwNi1ncmFudGVkLXRyYW5zbGF0ZWQgY29weSBvZiBwcmlvcml0eSBkb2N1bWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">42-kolnp-2006-granted-translated copy of priority document.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="227601-a-three-dimensional-battery-with-an-electrode-structure-and-a-method-for-producing-the-same.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="227603-filling-unit-for-filling-the-containers-with-products-in-particular-pharmaceutical-products.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>227602</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>42/KOLNP/2006</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>03/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>16-Jan-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>14-Jan-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>04-Jan-2006</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>MERCK PATENT GMBH</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>FRANKFURTER STRASSE 250, 64293 DARMSTADT</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>DORSCH, DIETER</td>
											<td>KONIGSBERGER STR 17A 64372 OBER-RAMSTADT</td>
										</tr>
										<tr>
											<td>2</td>
											<td>CEZANNE, BERTRAM</td>
											<td>BAHNSTRASSE 74 64546 MORFELDER-WALDORF</td>
										</tr>
										<tr>
											<td>3</td>
											<td>MEDERSKI, WERNER</td>
											<td>KATZELENBOGENWEG 1 64673 ZWINGENBERG</td>
										</tr>
										<tr>
											<td>4</td>
											<td>TSAKLAKIDIS, CHRISTOS</td>
											<td>IM LANGGEWANN 54 69469 WEINHEIM</td>
										</tr>
										<tr>
											<td>5</td>
											<td>WURZIGER, HANNS</td>
											<td>GREINSTRASSE 7B 64291 DARMSTADT</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 265/10</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2004/007938</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2004-07-16</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>103/36 716.0</td>
									<td>2003-08-11</td>
								    <td>Germany</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/227602-a-process-for-the-preparation-of-n-arylmorpholine-compound by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 07:35:52 GMT -->
</html>
